Skip to main content

Table 7 Patients’ concomitant medications

From: Early initiation of tolvaptan is associated with early discharge in patients with heart failure regardless of age

   < 80 years old  ≥ 80 years old P value
(n = 146) (n = 101)
Administration rate of TLV at discharge (n, %) 83, 50.0 47, 46.5 0.594
Dosage of TLV at discharge (mg/day) 8.30 ± 4.70 7.33 ± 3.92 0.092
Presence rate of RAS-I combined use at the start of TLV (n, %) 107, 73.3 83, 82.2 0.104
Administration rate of loop diuretics at discharge (n, %) 111, 76.0 82, 81.2 0.337
Dosage of loop diuretics at discharge (mg/day) 29.1 ± 23.3 24.5 ± 14.0 0.115
Administration rate of beta-blockers at discharge (n, %) 122, 83.6 80, 79.2 0.386
Administration rate of ACE-Is/ARBs at discharge (n, %) 90, 61.6 57, 56.4 0.414
  1. TLV: Tolvaptan, ACE-I: angiotensin converting enzyme inhibitor, ARB: angiotensin II receptor blocker. Continuous data are expressed as the mean ± standard deviation. P-values were determined using the unpaired t-test